Global Biosimilars Market - 2024-2033

February 2026 | 200 pages | ID: G5286331A912EN
DataM Intelligence

Abstracts

The Global Biosimilars Market was valued at US$ 30.30 Billion in 2024 and is anticipated to reach US$ 99.3 Billion by 2033, at a CAGR of 0.141 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Biosimilars Market.

This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Biosimilars Market Scope:

By Drug Class

• Monoclonal Antibodies (mAbs)
• Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Erythropoietin
• Human Growth Hormone
• Follitropin
• Interferons
• Anti-Vascular Endothelial Growth Factor
• Other Drug Classes

By Therapeutic Area

• Oncology
• Immunology & Autoimmune Diseases
• Metabolic Diseases (including diabetes)
• Neurology
• Infectious Diseases
• Rare Diseases
• Others

By Manufacturing Modality

• Mammalian Cell-Based Biosimilars
• Microbial-Based Manufacturing
• Plasma-Derived Manufacturing
• Other Manufacturing Platforms

By Route of Administration

• Intravenous
• Subcutaneous
• Intramuscular
• Others

By End-User

• Hospitals & Specialty Clinics
• Infusion Centers
• Specialty Pharmacies
• Others

Key Players

• Pfizer, Inc.
• Amgen Inc.
• Novartis AG (Sandoz division)
• Samsung Bioepis Co., Ltd.
• Celltrion, Inc.
• Biocon Limited
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Dr. Reddy’s Laboratories Ltd.
• STADA Arzneimittel AG
• Fresenius Kabi AG
• Apotex Inc.

Major Highlights

This report delivers a comprehensive overview of the Global Biosimilars Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Biosimilars Market. The Global Biosimilars Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Government-Led Switching and Tender Policies Accelerating Biosimilars Adoption in Public Health Systems
    3.1.1.2. Patent Expiry Wave of Blockbuster Biologics Unlocking Multi-Billion-Dollar Biosimilars Entry Windows
    3.1.1.3. Hospital and Payer Cost-Containment Programs Prioritizing Biosimilars in Treatment Protocols
  3.1.2. Restraints
    3.1.2.1. Interchangeability and Physician Confidence Barriers Slowing Automatic Substitution
    3.1.2.2. High Analytical and Clinical Comparability Costs Limiting New Entrant Participation
    3.1.2.3. Complex Cold-Chain and Bioprocess Manufacturing Requirements Increasing Operational Risk
  3.1.3. Opportunity
    3.1.3.1. Rapid Expansion of Biosimilars in Emerging Therapeutic Segments such as Ophthalmology and Rare Diseases
    3.1.3.2. Strategic Licensing and Co-Development Agreements Between Innovators and Biosimilars Developers
    3.1.3.3. Growth of Local Biomanufacturing Hubs in Asia and Latin America Supporting Export-Oriented Drug Class
  3.1.4. Trends
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter’s Five Force Analysis – Global Biosimilars
4.2. Geopolitical & Supply Chain Exposure
4.3. Social & Patient-Centric Factors
4.4. Economic Factors
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Biosimilars Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Biosimilars Market

5. BY DRUG CLASS

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  5.1.2. Market Attractiveness Index, By Drug Class
5.2. Monoclonal Antibodies (mAbs)*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors
5.4. Granulocyte Colony-Stimulating Factor (G-CSF)
5.5. Insulin
5.6. Erythropoietin
5.7. Human Growth Hormone
5.8. Follitropin
5.9. Interferons
5.10. Anti-Vascular Endothelial Growth Factor
5.11. Other Drug Classes

6. BY THERAPEUTIC AREA

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Immunology & Autoimmune Diseases
6.4. Metabolic Diseases (including diabetes)
6.5. Neurology
6.6. Infectious Diseases
6.7. Rare Diseases
6.8. Others

7. BY MANUFACTURING MODALITY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  7.1.2. Market Attractiveness Index, By Manufacturing Modality
7.2. Mammalian Cell-Based Biosimilars*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Microbial-Based Manufacturing
7.4. Plasma-Derived Manufacturing
7.5. Other Manufacturing Platforms

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intravenous *
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Intramuscular
8.5. Others

9. BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals & Specialty Clinics*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infusion Centers
9.4. Specialty Pharmacies
9.5. Others

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.8.1. US
    10.2.8.2. Canada
    10.2.8.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.8.1. Germany
    10.3.8.2. UK
    10.3.8.3. France
    10.3.8.4. Russia
    10.3.8.5. Italy
    10.3.8.6. Spain
    10.3.8.7. Norway
    10.3.8.8. Netherlands
    10.3.8.9. Sweden
    10.3.8.10. Denmark
    10.3.8.11. Belgium
    10.3.8.12. Switzerland
    10.3.8.13. Austria
    10.3.8.14. Poland
    10.3.8.15. Finland
    10.3.8.16. Rest of Europe
10.4. Latin America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.8.1. Brazil
    10.4.8.2. Argentina
    10.4.8.3. Rest of Latin America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.8.1. China
    10.5.8.2. India
    10.5.8.3. Japan
    10.5.8.4. Australia
    10.5.8.5. South Korea
    10.5.8.6. New Zealand
    10.5.8.7. Indonesia
    10.5.8.8. Malaysia
    10.5.8.9. Philippines
    10.5.8.10. Singapore
    10.5.8.11. Thailand
    10.5.8.12. Vietnam
    10.5.8.13. Rest of Asia-Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
  10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.6.8.1. UAE
    10.6.8.2. Saudi Arabia
    10.6.8.3. South Africa
    10.6.8.4. Israel
    10.6.8.5. Egypt
    10.6.8.6. Turkey
    10.6.8.7. Qatar
    10.6.8.8. Kuwait
    10.6.8.9. Oman
    10.6.8.10. Bahrain
    10.6.8.11. Rest of Middle East and Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

12.1. Pfizer, Inc.*
  12.1.1. Company Overview
  12.1.2. Product Portfolio
  12.1.3. Revenue Analysis
  12.1.4. Pricing Analysis
  12.1.5. SWOT Analysis
  12.1.6. Recent Developments
    12.1.6.1. Major Deals
    12.1.6.2. M&A
    12.1.6.3. Collaboration
    12.1.6.4. Acquisition
    12.1.6.5. Joint Ventures
    12.1.6.6. Innovations
  12.1.7. Recent News
    12.1.7.1. Events
    12.1.7.2. Conferences
    12.1.7.3. Symposiums
    12.1.7.4. Webinars
12.2. Amgen Inc.
12.3. Novartis AG (Sandoz division)
12.4. Samsung Bioepis Co., Ltd.
12.5. Celltrion, Inc.
12.6. Biocon Limited
12.7. Viatris Inc.
12.8. Teva Pharmaceutical Industries Ltd.
12.9. Boehringer Ingelheim International GmbH
12.10. Merck KGaA
12.11. F. Hoffmann-La Roche Ltd.
12.12. Dr. Reddy’s Laboratories Ltd.
12.13. STADA Arzneimittel AG
12.14. Fresenius Kabi AG
12.15. Apotex Inc. (LIST NOT EXHAUSTIVE)

13. GLOBAL BIOSIMILARS MARKET – RESEARCH METHODOLOGY

13.1. Research Data
  13.1.1. Secondary Data
  13.1.2. Primary Data
  13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
  13.2.1. Bottom-Up Approach
  13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us